Table 1.
Baseline Characteristics of Patients with Transarterial Chemoembolization (n=287)
| Characteristic | Value |
|---|---|
| Age, yr | 60.71±11.08 |
| Male sex | 208 (72.5) |
| Aetiology | |
| HBV | 172 (59.9) |
| HCV | 45 (15.7) |
| NBNC | 70 (24.4) |
| Albumin, g/dL | 3.49±0.69 |
| Total bilirubin, mg/dL | 1.0 (0.2–13.9) |
| Prothrombin time (%) | 84 (23–100) |
| MELD score | 6.25 (2.19–15.20) |
| Tumor stage (I, II/III, IV) | 118/169 (41.1/58.9) |
| Liver cirrhosis | 220 (76.7) |
| CTP score (A/B/C) | 192/80/15 (66.9/27.9/5.2) |
| AFP (>20 ng/mL) | 165 (57.5) |
| Tumor size (>5 cm) | 92 (32.1) |
| Nodularity (multinodular) | 165 (57.5) |
| TACE session (times) for CR (1/2/≥3) | 60/15/6 |
| Portal vein thrombosis | 46 (16) |
Data are presented as mean±SD, number (%), or median (range).
HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, nonhepatitis B and nonhepatitis C; MELD, model for end-stage liver disease; CTP, Child-Turcotte-Pugh; AFP, α-fetoprotein; TACE, transarterial chemoembolization; CR, complete response.